- Home
- RPTX vs MYO Comparison
RPTX vs MYO Comparison
Compare RPTX & MYO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RPTX
- MYO
- Stock Information
- Founded
- RPTX 2016
- MYO 2004
- Country
- RPTX Canada
- MYO United States
- Employees
- RPTX N/A
- MYO N/A
- Industry
- RPTX Biotechnology: Pharmaceutical Preparations
- MYO Industrial Specialties
- Sector
- RPTX Health Care
- MYO Health Care
- Exchange
- RPTX Nasdaq
- MYO Nasdaq
- Market Cap
- RPTX 141.1M
- MYO 157.9M
- IPO Year
- RPTX 2020
- MYO 2017
- Fundamental
- Price
- RPTX $1.32
- MYO $6.23
- Analyst Decision
- RPTX Strong Buy
- MYO Strong Buy
- Analyst Count
- RPTX 3
- MYO 4
- Target Price
- RPTX $7.00
- MYO $8.25
- AVG Volume (30 Days)
- RPTX 709.5K
- MYO 368.8K
- Earning Date
- RPTX 11-07-2024
- MYO 11-06-2024
- Dividend Yield
- RPTX N/A
- MYO N/A
- EPS Growth
- RPTX N/A
- MYO N/A
- EPS
- RPTX N/A
- MYO N/A
- Revenue
- RPTX $66,524,000.00
- MYO $25,239,125.00
- Revenue This Year
- RPTX $13.22
- MYO $53.19
- Revenue Next Year
- RPTX N/A
- MYO $39.01
- P/E Ratio
- RPTX N/A
- MYO N/A
- Revenue Growth
- RPTX 18.19
- MYO 36.23
- 52 Week Low
- RPTX $1.23
- MYO $2.51
- 52 Week High
- RPTX $8.49
- MYO $6.75
- Technical
- Relative Strength Index (RSI)
- RPTX 30.27
- MYO 61.36
- Support Level
- RPTX $1.23
- MYO $5.80
- Resistance Level
- RPTX $4.07
- MYO $6.14
- Average True Range (ATR)
- RPTX 0.34
- MYO 0.47
- MACD
- RPTX -0.20
- MYO -0.05
- Stochastic Oscillator
- RPTX 3.34
- MYO 57.33
About RPTX Repare Therapeutics Inc.
Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company's focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations. The company derives maximum revenue from Canada.
About MYO Myomo Inc.
Myomo Inc is a wearable medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. The MyoPro myoelectric upper limb orthosis product is registered with the Food and Drug Administration as a Class II medical device. The Company provides the devices to patients and bills their insurance companies directly, sometimes utilizing the clinical services of orthotics and prosthetics providers for which a fee is paid. The Company sells the product to orthotics and prosthetics providers around the world and the Veterans Health Administration (VA).